↓ Skip to main content

A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control

Overview of attention for article published in Nutrition Journal, March 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news
4 news outlets
blogs
4 blogs
twitter
25 X users
facebook
7 Facebook pages
video
3 YouTube creators

Citations

dimensions_citation
195 Dimensions

Readers on

mendeley
471 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control
Published in
Nutrition Journal, March 2011
DOI 10.1186/1475-2891-10-24
Pubmed ID
Authors

Marilyn L Barrett, Jay K Udani

Abstract

Obesity, and resultant health hazards which include diabetes, cardiovascular disease and metabolic syndrome, are worldwide medical problems. Control of diet and exercise are cornerstones of the management of excess weight. Foods with a low glycemic index may reduce the risk of diabetes and heart disease as well as their complications. As an alternative to a low glycemic index diet, there is a growing body of research into products that slow the absorption of carbohydrates through the inhibition of enzymes responsible for their digestion. These products include alpha-amylase and glucosidase inhibitors. The common white bean (Phaseolus vulgaris) produces an alpha-amylase inhibitor, which has been characterized and tested in numerous clinical studies. A specific and proprietary product named Phase 2® Carb Controller (Pharmachem Laboratories, Kearny, NJ) has demonstrated the ability to cause weight loss with doses of 500 to 3000 mg per day, in either a single dose or in divided doses. Clinical studies also show that Phase 2 has the ability to reduce the post-prandial spike in blood glucose levels. Experiments conducted incorporating Phase 2 into food and beverage products have found that it can be integrated into various products without losing activity or altering the appearance, texture or taste of the food. There have been no serious side effects reported following consumption of Phase 2. Gastro-intestinal side effects are rare and diminish upon extended use of the product. In summary, Phase 2 has the potential to induce weight loss and reduce spikes in blood sugar caused by carbohydrates through its alpha-amylase inhibiting activity.

X Demographics

X Demographics

The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 471 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 5 1%
Mexico 2 <1%
Canada 2 <1%
Indonesia 1 <1%
India 1 <1%
Czechia 1 <1%
United States 1 <1%
Unknown 458 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 84 18%
Student > Master 63 13%
Researcher 60 13%
Student > Ph. D. Student 57 12%
Other 24 5%
Other 77 16%
Unknown 106 23%
Readers by discipline Count As %
Agricultural and Biological Sciences 109 23%
Medicine and Dentistry 54 11%
Biochemistry, Genetics and Molecular Biology 46 10%
Chemistry 38 8%
Pharmacology, Toxicology and Pharmaceutical Science 30 6%
Other 69 15%
Unknown 125 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 83. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2022.
All research outputs
#457,320
of 23,544,633 outputs
Outputs from Nutrition Journal
#142
of 1,447 outputs
Outputs of similar age
#1,657
of 122,885 outputs
Outputs of similar age from Nutrition Journal
#5
of 19 outputs
Altmetric has tracked 23,544,633 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,447 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,885 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.